Altman Clinical and Translational Research Institute Building Opens March 4

Stunning structure will house array of scientists and centers dedicated to speeding basic research into new treatments and therapies —

Rising above Interstate 5 on the east campus of University of California, San Diego, the Altman Clinical and Translational Research Institute Building (ACTRI), a five-sided polygon of glass, steel and grooved concrete, officially opens its doors March 4 in a ribbon-cutting ceremony.

“The building is an architectural marvel, but more important is what it represents and the work that will go on inside,” said UC San Diego Chancellor Pradeep K. Khosla. … Read the Full Story from the UC San Diego Newsroom


Dr. Gary Firestein

Dr. Gary Firestein

The director of the Clinical and Translational Research Institute at UC San Diego is Gary S. Firestein, MD, Professor of Medicine and Dean and Associate Vice Chancellor of Translational Medicine at UC San Diego.

CTRI opened in 2010 as a part of the national Clinical and Translational Science Award consortium through a five-year, $37.2 million grant from the National Center for Advancing Translational Science of the National Institutes of Health. CTRI received a $52 million renewal grant last year.

More about the activities of the CTRI

 

$52M NIH Grant Advances Clinical and Translational Research at UC San Diego

Federal funding will help further on-going efforts to translate discoveries to clinic —

The Clinical and Translational Research Institute (CTRI) at University of California, San Diego has received a five-year Clinical and Translational Science Award (CTSA) for approximately $52 million from the National Center for Advancing Translational Science, part of the National Institutes of Health. … Read the full story from the UC San Diego News Center

Nanospheres Safely Deliver High Chemotherapy Doses in Response to Tumor Secretions

Scientists have designed nanoparticles that release drugs in the presence of a class of proteins that enable cancers to metastasize. That is, they have engineered a drug delivery system so that the very enzymes that make cancers dangerous could instead guide their destruction.

“We can start with a small molecule and build that into a nanoscale carrier that can seek out a tumor and deliver a payload of drug,” said Cassandra Callmann, a graduate student in chemistry and biochemistry at the University of California, San Diego, and first author of the report published in the journal Advanced Materials July 14. …Read the full story from the UC San Diego News Center

UC San Diego and GSK Collaborate to Eradicate Cancer Stem Cells, Treat Leukemia

First California institution selected to participate in GSK’s bench-to-bedside academia-industry collaboration program —

Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center are working with GSK on a bench-to-bedside project to treat leukemia and other diseases by eliminating cancer stem cells. The collaboration is part of GSK’s Discovery Partnerships with Academia (DPAc) program, where academic partners become core members of drug-hunting teams. Catriona Jamieson, MD, PhD, associate professor of medicine and chief of the Division of Regenerative Medicine, will lead UC San Diego’s effort in the new DPAc team. … Read the full story from the UC San Diego Newsroom

Leading Metabolics Researcher Joins UC San Diego School of Medicine

Alan Saltiel will head unified effort to create comprehensive diabetes center —

Alan R. Saltiel, PhD, whose studies of the hormone insulin have helped drive research of obesity, diabetes and other metabolic disorders across the nation, is joining University of California, San Diego School of Medicine as professor and director of a new Comprehensive Diabetes Center.

Saltiel, who most recently served as director of the Life Sciences Institute at University of Michigan, will bring together and expand UC San Diego’s diverse programs to better understand and treat diabetes and other metabolic disorders. … Read the full story from the UC San Diego Newsroom


Dr. Saltiel joins the Department of Medicine as professor in the Division of Endocrinology and Metabolism.

Protein’s Impact on Colorectal Cancer is Dappled

In early stages, it acts as tumor suppressor; later it can help spread disease —

Researchers at University of California, San Diego School of Medicine have discovered a cell signaling pathway that appears to exert some control over initiation and progression of colorectal cancer, the third leading cause of cancer-related death in the United States. A key protein in the pathway also appears to be predictive of cancer survival rates. … Read the full story from the UC San Diego Newsroom


Dr. Pradipta GhoshThe study’s senior author is Pradipta Ghosh, MD, associate professor of medicine in the Division of Gastroenterology.

Jill P. Mesirov Appointed Associate Vice Chancellor for Computational Health Sciences

UC San Diego School of Medicine recruits world leader in computational biology —

Leading computational biologist Jill P. Mesirov, PhD, has been appointed associate vice chancellor for computational health sciences and professor of medicine at University of California, San Diego School of Medicine and Moores Cancer Center. Mesirov most recently served as associate director and chief informatics officer at the Broad Institute of MIT and Harvard, where she directed the Computational Biology and Bioinformatics Program. … Read the full story from the UC San Diego Newsroom


Dr. Mesirov joins the Department of Medicine as a professor in the Division of Medical Genetics.

New Biomarkers Might Help Personalize Metastatic Colorectal Cancer Treatment

Low levels of two genes predicts positive response to chemotherapy and longer survival times —

Metastatic colorectal cancer patients tend to live longer when they respond to the first line of chemotherapy their doctors recommend. To better predict how patients will respond to chemotherapy drugs before they begin treatment, researchers at University of California, San Diego School of Medicine conducted a proof-of-principle study with a small group of metastatic colorectal cancer patients. The results, published June 17 in PLOS ONE, revealed two genes that could help physicians make more informed treatment decisions for patients with this disease. …Read the full story from the UC San Diego Newsroom

Paul Fanta, MD, MS

Paul Fanta, MD, MS

Senior author of the study is Department of Medicine oncologist Paul Fanta, MD, MS, Health Sciences associate clinical professor in the Division of Hematology-Oncology. Dr. Fanta is a researcher in the Solid Tumor Therapeutics Program at the UC San Diego Moores Cancer Center.

Read the article in PLOS ONE (Open Access)

Dietary Trans Fat Linked to Worse Memory

Higher consumption of dietary trans fatty acids (dTFA), commonly used in processed foods to improve taste, texture and durability, has been linked to worsened memory function in men 45 years old and younger, according to a University of California, San Diego School of Medicine study published online on June 17 in PLOS ONE. …Read the full story from the UC San Diego Newsroom

Principal investigator of the study is Beatrice A. Golomb, MD, PhD, professor in the Department of Medicine.

Drs. Joachim Ix, Davey Smith Elected to American Society for Clinical Investigation

Two Department of Medicine physician-scientists have been elected to the American Society for Clinical Investigation (ASCI) this year.

Dr. Joachim Ix

Dr. Joachim Ix

Joachim H. Ix, MD, MAS, FASN, a nephrologist and epidemiologist, is professor and chief of the Division of Nephrology-Hypertension. He holds a secondary appointment in the Division of Preventive Medicine, Department of Family and Preventive Medicine.

Dr. Davey Smith

Dr. Davey Smith

Translational research virologist Davey M. Smith, MD, MAS, professor of medicine in the Division of Infectious Diseases, directs the Center for AIDS Research Translational Virology Core and is medical director of the Early Intervention Program at the UC San Diego Antiviral Research Center.

ASCI membership is a distinction that recognizes the nation’s most outstanding physician-scientists.